Literature DB >> 17083475

Differential gene expression between human schwannoma and control Schwann cells.

C O Hanemann1, B Bartelt-Kirbach, R Diebold, K Kämpchen, S Langmesser, T Utermark.   

Abstract

The NF2 gene encodes the tumour suppressor protein merlin. The mutation of a single allele of this gene causes the autosomal dominantly inherited disease neurofibromatosis type 2 (NF2), which is characterized mainly by vestibular schwannoma carrying a second hit mutation. Complete lack of merlin is also found in spontaneous schwannomas and meningiomas. As the events leading to schwannoma development are largely unknown we investigated the differences in gene expression between schwannoma cells from NF2 patients and normal human primary Schwann cells by cDNA array analysis. We identified 41 genes whose expression levels differed by more than factor 2. Most of these clones were corroborated by real-time reverse transcription polymerase chain reaction analysis. By this method a total of seven genes with increased and seven genes with decreased mRNA levels in schwannoma compared with normal Schwann cells could be identified. Regulated clones, some of which not been described in Schwann cells earlier, included matrix metalloproteinase's, growth factors, growth factor receptors and tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083475     DOI: 10.1111/j.1365-2990.2006.00769.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  15 in total

1.  Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.

Authors:  Lu Zhou; Emanuela Ercolano; Sylwia Ammoun; M Caroline Schmid; Magdalena A Barczyk; Clemens Oliver Hanemann
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

3.  ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

Authors:  Sylwia Ammoun; Clare H Cunliffe; Jeffrey C Allen; Luis Chiriboga; Filippo G Giancotti; David Zagzag; C Oliver Hanemann; Matthias A Karajannis
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

4.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

5.  Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.

Authors:  Tina X Lee; Mark D Packer; Jie Huang; Elena M Akhmametyeva; Samuel K Kulp; Ching-Shih Chen; Marco Giovannini; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Eur J Cancer       Date:  2009-04-07       Impact factor: 9.162

6.  PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.

Authors:  Christine Flaiz; Jonathan Chernoff; Sylwia Ammoun; Jeffrey R Peterson; Clemens O Hanemann
Journal:  Exp Neurol       Date:  2009-05-03       Impact factor: 5.330

7.  The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Lu Zhou; David A Hilton; Magdalena Barczyk; Clemens Oliver Hanemann
Journal:  Mol Oncol       Date:  2014-08-27       Impact factor: 6.603

8.  Sporadic vestibular schwannomas associated with good hearing secrete higher levels of fibroblast growth factor 2 than those associated with poor hearing irrespective of tumor size.

Authors:  Sonam Dilwali; Andrew Lysaght; Daniel Roberts; Fred G Barker; Michael J McKenna; Konstantina M Stankovic
Journal:  Otol Neurotol       Date:  2013-06       Impact factor: 2.311

9.  Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Joceline Triner; Paul Manley; Clemens Oliver Hanemann
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

10.  The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.

Authors:  L Zhou; J Lyons-Rimmer; S Ammoun; J Müller; E Lasonder; V Sharma; E Ercolano; D Hilton; I Taiwo; M Barczyk; C O Hanemann
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.